

R&D Pipeline

Only high-priority projects in the clinical stage or soon to be in the clinical stage are listed in the table.



Code Generic name (Product name)	Indication	Preclinical	Clinical Trial	Application	Approval	Mechanism
JR-141* pabinafusp alfa (IZCARGO® for I.V. infusion 10mg)	MPS type II (Hunter)				Japan	BBB-penetrating iduronate-2-sulfatase (rDNA origin)
			Global Ph3			
JR-142 redalsomatropin alfa	Pediatric growth hormone deficiency		Japan Ph3			Long-acting human growth hormone (rDNA origin)
JR-171 lepunafusp alfa	MPS type I (Hurler etc.)		Global Ph1/2			BBB-penetrating α-L-iduronidase (rDNA origin)
JR-441	MPS type III A (Sanfilippo A)		Germany Ph1/2			BBB-penetrating heparan N-sulfatase (rDNA origin)
			Japan Ph1			
JR-446	MPS type III B (Sanfilippo B)		Japan Ph1/2			BBB-penetrating α-N-acetylglucosaminidase (rDNA origin) Partnering with MEDIPAL HOLDINGS
JR-471	Fucosidosis					BBB-penetrating α-L-fucosidase (rDNA origin) Partnering with MEDIPAL HOLDINGS
JR-479	GM2 gangliosidosis					BBB-penetrating β-hexosaminidase A (rDNA origin) Partnering with MEDIPAL HOLDINGS